SOUTH SAN FRANCISCO, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of ...

Learn the key differences between obstructive and nonobstructive HCM, including how your specific diagnosis can impact ...

ACACIA-HCM is a Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of aficamten compared to placebo on health-related quality of life in ...

Many drugs available and in development work by targeting proteins, an approach that comes with limitations. For one, proteins are not the root cause of disease, said Samir Ounzain, co-founder and CEO ...

SONATA-HCM is the only ongoing Phase 3 study in both obstructive and non-obstructive HCM. It is a randomized, double-blind, placebo-controlled multicenter trial that will evaluate the efficacy of ...

Advances development of ninerafaxstat, a potential first-in-class therapy designed to improve cardiac energetics in patients with serious cardiovascular diseases Enrollment underway across U.S. sites ...

SOUTH SAN FRANCISCO, Calif., May 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that additional data arising from two analyses from SEQUOIA-HCM, (Safety, Efficacy, and ...

Cytokinetics, Incorporated announced findings from two analyses of the SEQUOIA-HCM trial that studied the effects of aficamten on patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM ...

Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...